

18. MEDIGARD (MGZ)

CEO: Peter Emery

Year established: 1999, listed 2004

Revenue '08: N/A

Total staff: 7

A RELATIVELY new player in the market, Medigard is responsible for producing innovative medical devices distributed throughout the global marketplace.

Although the company has been listed on the ASX since 2004, it is very much still in its developmental stages.

The company is focussing on preventing needlestick injuries, which have the potential to infect users with up to 20 bloodborne diseases including HIV-AIDS and Hepatitis B and C.

CEO Peter Emery believes 2009 will be a challenging year for the business community with lack of credit, volatility, and continued poor performance of the sharemarket, and a decline in the general business environment. He is, however, certain of Medigard's goals.

"For Medigard there is a need to get deals done," says Emery.

"Credit is tight and the recession is yet to hit and bite, as a city and economic centre, we need to remain positive and seek out opportunities."

In a major coup, the company has received approval to sell its patented blood collection device in the United States.

Acquisition plans/new projects

- Medigard has designed and developed a range of safety medical devices which it plans to bring to the global market through licensing or distribution partnerships
- Longer term, the company will grow by the introduction of more products and also by acquisitions

